GrÃ¼nenthal Boosts Pain Drug PortfolioBy
Grünenthal, an Aachen, Germany-headquartered research-based pharmaceutical company, has acquired Thar Pharmaceuticals, a Pittsburgh, Pennsylvania-based clinical-stage specialty pharmaceutical company, to expand its development portfolio for treating complex regional pain syndrome (CRPS). With this acquisition, Grünenthal gets the worldwide development and commercialization rights for Thar Pharmaceuticals’ lead development candidate, T121, a patented oral zoledronic acid drug product.
Thar Pharmaceuticals is focused on transforming intravenous-only drugs into oral drugs for existing and new indications using its Enhance development platform. Its lead candidate broadens Grünenthal’s portfolio for CRPS, which includes intravenous neridronate, currently in Phase III clinical development. Grünenthal will conduct Phase III development of T121 for the treatment of patients with CRPS.